Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 594-600

  Estrada Gonzalez P K ^a,c   Gomez Ceja L ^a,c   Montesinos, J J ^a   Mayani, H ^a   Chavez Gonzalez A ^a   Meillon L ^b   Delgado, N ^b   Sanchez Nava E ^b   Flores Figueroa, E ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Bone remodeling; Chronic myeloid leukemia; Fibrosis; Imatinib; Mesenchymal stromal cells

Indexed keywords

BONE REMODELING; CHRONIC MYELOID LEUKEMIA; FIBROSIS; IMATINIB; MESENCHYMAL STROMAL CELLS;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL DIFFERENTIATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MESENCHYMAL STROMAL CELLS; PHENOTYPE; PIPERAZINES; PYRIMIDINES;

EID: 84899065911     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.02.011     Document Type: Article

References (34)

1. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
2. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
3. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
4. Berman E., Nicolaides M., Maki R.G., Fleisher M., Chanel S., Scheu K., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006, 354:2006-2013.
5. Jönsson S., Olsson B., Ohlsson C., Lorentzon M., Mellström D., Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008, 93:1101-1103.
6. Fitter S., Dewar A.L., Kostakis P., To L.B., Hughes T.P., Roberts M.M., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2009, 111:2538-2547.
7. O'Sullivan S., Horne A., Wattie D., Porteous F., Callon K., Gamble G., et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009, 94:1131-1136.
8. Osorio S., Noblejas A.G., Durán A., Steegmann J.L. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007, 82:394-395.
9. Jabbour E., Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012, 87:1037-1045.
10. Fierro F., Illmer T., Jing D., Schleyer E., Ehninger G., Boxberger S., et al. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007, 40:355-366.
11. Tibullo D., Giallongo C., La Cava P., Berretta S., Stagno F., Chiarenza A., et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009, 37:461-468.
12. O'Sullivan S., Naot D., Callon K., Porteous F., Horne A., Wattie D., et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res Off J Am Soc Bone Miner Res 2007, 22:1679-1689.
13. Fitter S., Vandyke K., Gronthos S., Zannettino A.C.W. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 2012, 48:229-240.
14. Flores-Figueroa E., Arana-Trejo R.M., Gutiérrez-Espíndola G., Pérez-Cabrera A., Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 2005, 29:215-224.
15. Montesinos J.J., Flores-Figueroa E., Castillo-Medina S., Flores-Guzmán P., Hernández-Estévez E., Fajardo-Orduña G., et al. Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 2009, 11:163-176.
16. Chávez-González A., Ayala-Sánchez M., Sánchez-Valle E., Ruiz-Sánchez E., Arana-Trejo R.M., Vela-Ojeda J., et al. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures. Leuk Res 2006, 30:286-295.
17. Flores-Figueroa E., Montesinos J.J., Flores-Guzmán P., Gutiérrez-Espíndola G., Arana-Trejo R.M., Castillo-Medina S., et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 2008, 32:1407-1416.
18. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
19. Jootar S., Pornprasertsud N., Petvises S., Rerkamnuaychoke B., Disthabanchong S., Pakakasama S., et al. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res 2006, 30:1493-1498.
20. Zhao Z., Tang X., You Y., Li W., Liu F., Zou P. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia. Leuk Res 2006, 30:993-1003.
21. Carrara R.C., Orellana M.D., Fontes A.M., Palma P.V., Kashima S., Mendes M.R., et al. Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant. Braz J Med Biol Res. 2007, 40:57-67.
22. Shirasaki R., Tashiro H., Mizutani-Noguchi M., Kawasugi K., Shirafuji N. Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: effect of vascular endothelial growth factor on development of the microenvironment. Leuk Res 2011, 35:663-669.
23. Rosu-Myles M., She Y.-M., Fair J., Muradia G., Mehic J., Menendez P., et al. Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells. PloS One 2012, 7:e38954.
24. Zhao Z.G., Xu W., Sun L., Li W.-M., Li Q.-B., Zou P. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia. Eur J Cancer 2012, 48:1884-1895.
25. Jones E.A., English A., Kinsey S.E., Straszynski L., Emery P., Ponchel F., et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom 2006, 70:391-399.
26. Li J., Wong W.H.-S., Chan S., San Chim J.C., Cheung K.M.-C., Lee T.-L., et al. Factors affecting mesenchymal stromal cells yield from bone marrow aspiration. Chin J Cancer Res 2011, 23:43-48.
27. Schepers K., Pietras E.M., Reynaud D., Flach J., Binnewies M., Garg T., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13:285-299.
28. Fitter S., Dewar A.L., Kostakis P., To L.B., Hughes T.P., Roberts M.M., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111:2538-2547.
29. Jönsson S., Hjorth-Hansen H., Olsson B., Wadenvik H., Sundan A., Standal T. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 2012, 3:119-123.
30. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
31. Mucke H. The role of imatinib in the treatment of pulmonary hypertension. Drugs Today 2013, 49:203-211.
32. Jaeger B.A., Tauer J.T., Ulmer A., Kuhlisch E., Roth H.J., Suttorp M. Changes in bone metabolic parameter in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit. 2012, 18:CR721-CR728.
33. Dewar A.L., Farrugia A.N., Condina M.R., Bik To L., Hughes T.P., Vernon-Roberts B., et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006, 107:4334-4337.
34. Flores-Figueroa E., Varma S., Montgomery K., Greenberg P.L., Gratzinger D. Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. Lab Investig 2012, 92:1330-1341.